Ipca Laboratories
Ipca Laboratories Limited, headquartered in Mumbai, India, is a prominent player in the pharmaceutical industry, specialising in the manufacture and export of active pharmaceutical ingredients (APIs) and finished dosage forms. Founded in 1949, the company has achieved significant milestones, including a robust presence in over 100 countries and a diverse product portfolio that encompasses a wide range of therapeutic areas such as cardiovascular, anti-infective, and pain management. With a commitment to quality and innovation, Ipca Laboratories stands out for its extensive range of generic formulations and APIs, which are produced in state-of-the-art facilities adhering to international standards. The company has garnered a strong market position, recognised for its consistent growth and contributions to healthcare, making it a trusted name in the global pharmaceutical landscape.
DitchCarbon Score
How does Ipca Laboratories's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Medical Device Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Ipca Laboratories's score of 19 is higher than 72% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Ipca Laboratories's reported carbon emissions
In 2024, Ipca Laboratories reported total carbon emissions of approximately 311,883,000 kg CO2e, comprising 174,538,000 kg CO2e from Scope 1 and 137,345,000 kg CO2e from Scope 2. This marks a significant increase in emissions compared to 2023, where the company recorded about 304,923,000 kg CO2e, with Scope 1 emissions remaining constant at 124,880,000 kg CO2e and Scope 2 emissions decreasing to 179,114,000 kg CO2e. Ipca Laboratories has set ambitious climate commitments, aiming for a 20% reduction in carbon emissions across both Scope 1 and Scope 2 by 2030, starting from their 2022 baseline. This commitment reflects the company's proactive approach to addressing climate change and reducing its carbon footprint in the pharmaceutical industry. As the company continues to monitor and report its emissions, these targets underscore its dedication to sustainability and environmental responsibility.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2022 | 2023 | 2024 | |
|---|---|---|---|
| Scope 1 | 124,880,000 | 000,000,000 | 000,000,000 |
| Scope 2 | 179,114,000 | 000,000,000 | 000,000,000 |
| Scope 3 | - | - | - |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Ipca Laboratories is not committed to any reduction initiatives we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
